Supported by Investors Who Share our Vision of Re-imagining Cancer Surgery

Vergent has raised over $34 million USD in financing, led by visionary investors in the biotech and medtech industries. Our investors include:

“We are grateful for the support from this world-class group of investors who share our belief that VGT-309 is a highly differentiated imaging agent that will help surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.” -- John Santini, PhD, president and chief executive officer at Vergent Bioscience.